Oncología Traslacional
ONCTRAS
Instituto Valenciano de Oncologia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Instituto Valenciano de Oncologia (33)
2024
-
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266
-
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer
Clinical Therapeutics, Vol. 46, Núm. 8, pp. 612-621
-
Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study
BMC Cancer, Vol. 24, Núm. 1
-
SENECA study: staging endometrial cancer based on molecular classification
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 9, pp. 1313-1321
-
SEOM-GEICO Clinical Guidelines on cervical cancer (2023)
Clinical and Translational Oncology
-
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation
Molecular Cancer, Vol. 23, Núm. 1
2023
-
A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer
Frontiers in Immunology, Vol. 14
-
ASO Visual Abstract: Accuracy and Survival Outcomes After National Implementation of Sentinel Lymph Node Biopsy in Early-Stage Endometrial Cancer
Annals of surgical oncology, Vol. 30, Núm. 12, pp. 7669-7670
-
Accuracy and Survival Outcomes after National Implementation of Sentinel Lymph Node Biopsy in Early Stage Endometrial Cancer
Annals of Surgical Oncology, Vol. 30, Núm. 12, pp. 7653-7662
-
Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients
Journal of Translational Medicine, Vol. 21, Núm. 1
-
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: Multicenter, phase Ib dose escalation and expansion study
International Journal of Gynecological Cancer, Vol. 33, Núm. 4, pp. 562-570
-
The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO Study
Cancers, Vol. 15, Núm. 11
2022
-
Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study
Journal of Personalized Medicine, Vol. 12, Núm. 11
-
Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study
Cancers, Vol. 14, Núm. 4
-
Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network
Cancers, Vol. 14, Núm. 8
2021
-
Management of advanced ovarian cancer in Spain: an expert Delphi consensus
Journal of Ovarian Research, Vol. 14, Núm. 1
2019
-
Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy
European Journal of Cancer, Vol. 117, pp. 99-106
-
Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer
Anti-Cancer Drugs, Vol. 30, Núm. 6, pp. 628-635
-
Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study
Cancer Chemotherapy and Pharmacology, Vol. 84, Núm. 4, pp. 781-789
2018
-
Erratum to: Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2018), 20, 3, (274-285), 10.1007/s12094-017-1719-x)
Clinical and Translational Oncology